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Some familial platelet disorders are associated with predisposition to leukemia, myelodysplastic 
syndrome (MDS) or dyserythropoietic anemia.1,2 We have identified a family with autosomal 
dominant thrombocytopenia, high red blood cell mean corpuscular volume (MCV) and two 
occurrences of precursor B cell acute lymphoblastic leukemia (ALL). Whole exome sequencing 
identified a heterozygous single nucleotide change in ETV6 (Ets Variant Gene 6), c.641C>T, 
encoding a p.Pro214Leu substitution in the central domain of the protein, which segregated 
exclusively with the thrombocytopenia and elevated MCV phenotype. Twenty-three additional 
families with a similar phenotype from a European consortium were screened, and two families 
were found to have mutations in ETV6. One family from the Czech Republic had the same 
p.Pro214Leu mutation with one individual developing B-cell ALL. The other family from Italy had 
a c.1252A>G nucleotide change that determined a p.Arg418Gly substitution in the DNA binding 
domain, as well as alternative splicing and exon skipping. Functional characterization of these 
mutations showed aberrant cytoplasmic localization of mutant and endogenous ETV6, 
decreased transcriptional repression by the ETV6 mutants, and altered maturation in 
hematopoietic cells cultured to become megakaryocytes. Our findings underscore a key role for 
ETV6 in platelet formation and leukemia predisposition. 
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ETV6 (also known as TEL) encodes a transcriptional repressor in the ETS family.3  ETV6 was 
initially identified as a tumor suppressor by involvement in somatic translocations in childhood 
leukemia, including ETV6-RUNX1, which often co-occur with a somatic mutation in the intact 
ETV6 allele, suggesting that loss of function contributes to the development of leukemia.4-6 
Somatic ETV6 mutations have also been described in patients with myelodysplastic syndrome 
(MDS) and T-cell leukemias,7,8 but thus far germline mutations have not been described. ETV6 
also has a critical role in hematopoiesis, as demonstrated in animal models.9,10 
Erythroid/megakaryocytic conditional Etv6 knockout mice are thrombocytopenic, and 
megakaryocyte colony formation is absent in homozygous knockout hematopoietic cells and 
decreased in heterozygotes, indicating Etv6 involvement in thrombopoiesis.11,12 Etv6 is also one 
of four transcription factors found sufficient to differentiate mouse fibroblasts into hematopoietic 
lineage cells.13 
 
We present here three families with germline mutations in ETV6 and defects in hematopoiesis. 
Affected members (n=5) in the original family from the United States (Family 1 Fig 1a) have 
variable thrombocytopenia (67,000-132,000 platelets/uL) and elevated red cell MCV (92.5-101.5 
fL), suggesting a defect affecting megakaryocytic-erythroid precursors. Hematocrit and other 
hematologic indexes are within normal ranges (Supplementary Table 1). Platelets have normal 
mean volume and ultrastructure, with some elongated alpha granules (Supplementary Fig 1). 
Patients exhibit mild to moderate bleeding, and two developed precursor B cell ALL, at ages 3 
(III-1) and 37 (II-7). Histopathological analysis of bone marrow from affected individuals without 
leukemia revealed small, hypolobulated megakaryocytes and abnormal red blood cell precursors 
(Fig 1b).  
 
Whole exome sequencing of Family 1 revealed a heterozygous single nucleotide change in 
ETV6, which segregated completely with thrombocytopenia and high red blood cell MCV. This 
missense variant, c.641C>T, encodes a proline to leucine amino acid change (p.Pro214Leu) in 
the central domain of ETV6 (Fig 1c) that was not found in 1000 Genomes or dbSNP databases 
and was predicted to be possibly damaging by PolyPhen2. Twenty-three additional European 
families with autosomal dominant thrombocytopenia, high red blood cell MCV and increased 
incidence of leukemia were screened via Sanger sequencing of exons and exon-intron 
boundaries of ETV6. This approach found two families with germline ETV6 mutations, one 
(Family 2, Fig 1a) with affected members having platelet counts of 44,000 -115,000 platelets/uL, 
MCV of 88-97 fL and ALL in individual I-2 at age 14, exhibited the identical c.641C>T mutation. 
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The other (Family 3, Fig 1a) with platelet counts of 99,000-101,000 platelets/uL and MCV of 93-
98 fL, but no malignancies had a mutation in the DNA- binding domain (c.1252A>G, 
p.Arg418Gly) not observed in 1000 Genomes and predicted to be highly damaging by 
PolyPhen2. Sequence alignment demonstrated that both mutations affect amino acids that are 
highly conserved across multiple species (Supplementary Information). 
 
The c.1252A>G mutation is located in the last codon of exon 7, which is split with exon 8, raising 
the possibility of this variant disrupting a splice site. To test this possibility RNA was isolated from 
peripheral blood cells from two individuals with the c.1252A>G mutation. RT-PCR detected two 
different transcripts, one of expected size (386 bp) and another of 285 bp, indicating an 
alternatively-spliced product (Supplementary Fig 2). Sequencing of the 285bp product revealed 
skipping of exon 7. This c.1153_1253del mutation is predicted to cause a partial deletion of the 
putative DNA binding domain (aa 385-418, p.385_418del) and a subsequent p.Asn385Valfs*7 
frameshift alteration resulting in a premature stop codon raising the possibility of a truncated 
protein. Although this truncated protein was expressed in transfection assays in HEK293T cells 
(Supplementary Fig 3) it was not detected in patients’ platelets (Supplementary Fig 4), 
suggesting it is not functional in megakaryocytes. The alternative splicing did not affect all mutant 
RNA, since sequencing of the 386 bp RT-PCR product, as well as plasmids where this product 
was cloned, showed the presence of the G nucleotide in addition to the wild type A, indicating 
that the p.Arg418Gly form of ETV6 is likely to be expressed in patients from this family. This type 
of genetic aberration, in which an exonic mutation creates an alternative splice site as well as an 
amino acid change, has been observed in other hematological disorders such as Hemoglobin E 
disease.14  
 
ETV6 is a 57kD protein with 452 amino acids and three functional domains: N-terminal pointed 
(PNT), central regulatory and C-terminal DNA-binding (ETS; Fig 1c). Nuclear localization and 
transcriptional repression activity of ETV6 require homodimerization via the pointed domain.15 
ETV6 modulates the activity of other ETS transcription factors such as FLI1, where hemizygous 
deletions cause Paris-Trousseau related thrombocytopenia,16,17 and several other known ETV6 
interaction partners that are present in platelets,18,19 and presumably megakaryocytes. The 
function of the central domain is not well understood, but it has been shown to undergo 
posttranslational modifications and to be essential for the repressive function of ETV6 in in vitro 
reporter assays.20  
 
 6 
To investigate the effect of the p.Pro214Leu, p.Arg418Gly, and p.385_418del mutations on ETV6 
transcriptional repression we used an in vitro reporter assay to measure luciferase expression 
induced by the promoter of the known ETV6 target stromelysin-1.8,21 As expected, wild type 
ETV6 (WT) repressed luciferase expression compared to empty vector. Expression of each of 
the three mutant forms of ETV6 resulted in less transcriptional repression when expressed alone 
or WT ETV6 (Figure 1d). Protein expression of WT and all ETV6 mutants in transfected cells 
were determined to be equivalent by immunoblot, suggesting that these mutations do not 
influence protein stability (Supplementary Fig 3).  
 
Thrombopoiesis involves a complex sequence of cellular events in bone marrow 
megakaryocytes culminating with the elaboration of proplatelet extensions that release platelets 
into the circulation. Approximately 1011 platelets must be produced daily to maintain normal 
concentrations of 150-400 x 109 platelets per liter of human blood.22 To determine the effect of 
P214L and R418G ETV6 on megakaryocyte differentiation human CD34+ cells were transduced 
with lentivirus containing WT, P214L or R418G ETV6 alleles and cultured with thrombopoietin to 
support megakaryocyte development.  P214L and R418G ETV6-transduced cells showed 
delayed/decreased maturation when compared to those transduced with WT ETV6, indicated by 
increased numbers of small, immature megakaryocytes (similar to the abnormalities observed in 
the bone marrow of affected individuals, Fig 1b) and decreased generation of proplatelets (Fig 2 
a-d).  These findings indicate that these mutations affect megakaryocyte development and likely 
platelet production.  
 
Since ETV6 requires dimerization to exert transcriptional repression, it is possible that the 
P214L, R418G and p.385-418del mutants may affect this interaction in a dominant negative 
manner. All mutants were shown to dimerize with wild type ETV6, demonstrated by concomitant 
“pull down” of both differentially tagged his-ETV6 WT and myc-ETV6 mutants (Supplementary 
Fig 5). The intracellular distribution of protein produced by transduced P214L or R418G and WT 
forms of ETV6 in megakaryocytes was examined by immunofluorescence staining for their myc 
tag, which showed expected nuclear localization for WT ETV6, while P214L and R418G ETV6 
were concentrated in the cytoplasm (Supplementary Figure 6). Staining for ETV6 (Figure 3) 
showed this protein concentrated in the nuclei of an untransduced control and WT-transduced 
cells, and largely in the cytoplasm of cells expressing mutant ETV6 (see also Videos 1-4).  These 
results indicate that the mutant forms of ETV6 mislocalize inside cells, and by dimerizing with 
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endogenous WT protein, may also prevent nuclear localization, further compromising ETV6 
repression activity.  
 
Several cases of leukemia involving somatic ETV6 alterations have been associated with loss of 
ETV6 function.4-6 In order to identify additional genetic aberrations contributing to 
leukemogenesis, whole exome and RNA sequencing were performed on leukemia blast cells 
from time of diagnosis, and from bone marrow cells after remission in the same patient (III-1, 
Family 1). RNA sequencing revealed that the wild type ETV6 allele was structurally normal and 
that wild type and p.P214L transcripts were expressed at equal amounts in the bone marrow 
samples. Several genetic variants and a novel gene fusion between PAX5 and SHB were found 
in the leukemia sample and were not present in the remission sample (Supplementary Table 2). 
These variants may represent candidate cooperative mutations with the germline ETV6 mutation 
in the development of leukemia. 23, 24  
 
In summary, we present novel germline mutations in ETV6, a gene known to be involved in 
human leukemogenesis and murine and zebra fish hematopoiesis, in three families with 
thrombocytopenia and high red cell MCV and leukemia predisposition in two of the three families. 
The p.Pro214Leu and p.Arg418Gly mutations partially disrupt ETV6 transcriptional repression in 
vitro and cause aberrant cytoplasmic localization in megakaryocytes, suggesting a dominant 
negative phenotype due to the requirement of ETV6 dimerization and nuclear localization for 
transcriptional repression. The p.Pro214Leu and the p.Arg418Gly mutations also impair 
development of megakaryocytes in culture. The mutations in these families reveal the 
implications of viable germline mutations in ETV6, and provide insights into the importance of 
ETV6 for platelet biology and tumor suppressor activity. 
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Figure Legends 
Figure 1. Mutation analysis of ETV6. (a) Pedigrees for three affected families. Solid symbols 
represent affected individuals with thrombocytopenia and high red cell mean corpuscular volume. 
Asterisks represent individuals that developed B cell leukemia. (Supplementary Table 1 shows 
all CBC values for affected and non-affected individuals). (b) Representative images of a bone 
marrow aspirate for one of the affected individuals without leukemia that shows mild 
dyserythropoiesis in the left panel (yellow arrows) and an immature hypolobulated 
megakaryocyte (yellow arrow) on the right panel. (c) Schematic of ETV6, which is composed of 8 
exons encoding untranslated regions (yellow) and protein coding sequences (blue). Two 
mutations, c.641C>T in exon 5 and c.1252A>G in exon 7 are depicted. In the lower section of the 
panel a schematic of ETV6 is represented with its different domains, pointed (PNT), central and 
ETS (which is the DNA-binding domain) and the location of the amino acid changes. (d) Effects 
of ETV6 mutant alleles (p.Pro214Leu, p.Arg418Gly, and p.385_418del) in the activity of an 
ETV6-responsive reporter plasmid (pGL2-754TR) when expressed alone or with the wild type 
allele. Luciferase activity, represented here by fold repression, is shown relative to empty vector 
and normalized using an internal control plasmid expressing Renilla luciferase. Wild type ETV6 
(WT) repressed luciferase expression by approximately 7.5 fold compared to empty vector, 
whereas p.P214L ETV6, p.R418G, and p.385_418del repressed transcription 4.5, 1.5, and 1.5 
fold, respectively (p<0.0001, one way ANOVA) (Figure 1d). Co-expression of WT and mutant 
proteins caused intermediate repression of the stromelysin-1 promoter. Experiments were done 
in triplicates and repeated at least 4 times. 
 
Figure 2. Abnormal development of day 12 cultured megakaryocytes expressing mutant 
ETV6. Control cells and those transduced with lentiviral myc-tagged forms of ETV6 (ETV6WT, 
ETV6P214L and ETV6R418G) were assessed via immunofluorescence microscopy imaging. (a-c) 
Megakaryocytes (control cells shown) were identified via expression of CD61 (violet) and VWF 
(red) and staged by diameter: <15 m (a), >15m (b), or the presence of proplatelets (c). (d) 
Population distributions showed no significant differences between control and ETV6WT-
transduced cells, while ETV6P214L-transduced megakaryocytes showed a significantly higher 
proportion (*P<0.05, 2-tailed t-test) of cells in the earlier developmental stage (<15 m) and 
fewer in the mature proplatelet-forming stage (control: n=7, WT: n=3, P214L: n=3, R418G: n=4 
cultures with >300 cells for each). Images for control cells and those transduced with WT, P214L 
and R418G forms of ETV6 are shown in Supplementary Fig 6. 
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Figure 3. Aberrant cytoplasmic localization of ETV6 in cultured megakaryocytes 
transduced with ETV6 mutants. Comparison via immunofluorescence microscopy of ETV6 
localization in Day 12 cultured control megakaryocytes and those transduced with lentiviral wild-
type (ETV6WT) or mutant (ETV6P214L, ETV6R418G) myc-tagged forms of ETV6. Confocal Z-sections 
of representative mature cells (>15m) are shown stained for DNA (blue), ETV6 (both 
endogenous and myc-tagged; green) and myc (red). In control cells endogenous ETV6 is 
concentrated in the nucleus, as is endogenous and myc-tagged WT ETV6 in cells transduced 
with ETV6WT. In contrast, cells transduced with mutant myc-tagged ETV6 (ETV6P214L, ETV6R418G) 
show this protein concentrated in the cytoplasm with little visible in the nucleus. Scale bars = 5 
m. See also Videos 1-4.  
 



